Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Caroen

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 23, 2020
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-makingChristopher Larson, Bryan Oronsky, Sharad Goyal, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Future Oncology (London, England)|September 12, 2019
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 16, 2023
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck ChemoradiotherapyMarcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, et al.
Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.
Future Oncology (London, England)|August 11, 2022
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumorsSantosh Kesari, Alberto Bessudo, Brian R Gastman, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 23, 2020
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-makingChristopher Larson, Bryan Oronsky, Sharad Goyal, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Future Oncology (London, England)|September 12, 2019
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancerBryan Oronsky, Tony R Reid, Christopher Larson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 16, 2023
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck ChemoradiotherapyMarcelo Bonomi, Dukagjin M Blakaj, Rafi Kabarriti, et al.
Clinical Medicine Insights. Oncology|November 15, 2016
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001Bryan Oronsky, Scott Caroen, Karen Zeman, et al.
Future Oncology (London, England)|August 11, 2022
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumorsSantosh Kesari, Alberto Bessudo, Brian R Gastman, et al.
Pageof 6